Wanjia Group (00401.HK) Contradictory Stock Price Report and Business Financial Analysis
Unlock More Features
Login to access AI-powered analysis, deep research reports and more advanced features
About us: Ginlix AI is the AI Investment Copilot powered by real data, bridging advanced AI with professional financial databases to provide verifiable, truth-based answers. Please use the chat box below to ask any financial question.
Related Stocks
Some reports indicate that Wanjia Group (00401.HK) is one of the best-performing stocks globally in 2025, with a year-to-date increase of 210.6%[0][2], but recent data shows its stock price dropped by 6.67% to HK$0.140 currently[0][5].
The company’s core business is hemodialysis services[0]. In H1 2025, revenue increased by 2.40% year-on-year to HK$85.706 million, but the operating loss attributable to shareholders was HK$712,000[0].
The hemodialysis industry has development potential supported by policies[0], but the company has a small market capitalization (about HK$78.43 million) and limited liquidity[0].
It is necessary to note the difference in the time scope of reports: some data reflect H1 performance, while others are recent real-time stock price changes[0].
Insights are generated using AI models and historical data for informational purposes only. They do not constitute investment advice or recommendations. Past performance is not indicative of future results.
About us: Ginlix AI is the AI Investment Copilot powered by real data, bridging advanced AI with professional financial databases to provide verifiable, truth-based answers. Please use the chat box below to ask any financial question.